Alarmin molecule identified as therapeutic target for allergic respiratory diseases

One of the molecules responsible for triggering the inflammation that causes allergic respiratory diseases, such as asthma and allergic rhinitis, has just been discovered by scientists from the CNRS, Inserm and the Université Toulouse III – Paul Sabatier.

AstraZeneca, CRISPR tools supplier ink gene editing enzyme licensing deal

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

January 14, 2025

Ibex Launches Breast Cancer Biomarker Diagnostic Platform

What You Should Know: Ibex Medical Analytics launches Galen Breast HER2™, a novel breast cancer AI-powered biomarker scoring solution developed in collaboration with AstraZeneca and Daiichi Sankyo, to

September 8, 2023

Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & Hepatology – Biotech Investments

Issuer: Immunic AG / Key word(s): Scientific publication 13.11.2024 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic Announces

November 14, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.